Evidence map›Paper›PMID 30261841›Full record

ArticleMolecular medicine (Cambridge, Mass.)2018

Leukemia inhibitory factor inhibits erythropoietin-induced myelin gene expression in oligodendrocytes.

Georgina Gyetvai, Cieron Roe, Lamia Heikal, Pietro Ghezzi, Manuela Mengozzi

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Georgina GyetvaiDepartment of Clinical and Experimental Medicine, Brighton & Sussex Medical School, Brighton, BN1 9PS, UK.
Cieron RoeDepartment of Clinical and Experimental Medicine, Brighton & Sussex Medical School, Brighton, BN1 9PS, UK.
Lamia HeikalDepartment of Clinical and Experimental Medicine, Brighton & Sussex Medical School, Brighton, BN1 9PS, UK.
Pietro GhezziDepartment of Clinical and Experimental Medicine, Brighton & Sussex Medical School, Brighton, BN1 9PS, UK. P.Ghezzi@bsms.ac.uk.ORCID http://orcid.org/0000-0003-0911-8358
Manuela MengozziDepartment of Clinical and Experimental Medicine, Brighton & Sussex Medical School, Brighton, BN1 9PS, UK.
Brighton and Sussex Medical School · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pro-myelinating effects of leukemia inhibitory factor (LIF) and other cytokines of the gp130 family, including oncostatin M (OSM) and ciliary neurotrophic factor (CNTF), have long been known, but controversial results have also been reported. We recently overexpressed erythropoietin receptor (EPOR) in rat central glia-4 (CG4) oligodendrocyte progenitor cells (OPCs) to study the mechanisms mediating the pro-myelinating effects of erythropoietin (EPO). In this study, we investigated the effect of co-treatment with EPO and LIF.

methodsGene expression in undifferentiated and differentiating CG4 cells in response to EPO and LIF was analysed by DNA microarrays and by RT-qPCR. Experiments were performed in biological replicates of N ≥ 4. Functional annotation and biological term enrichment was performed using DAVID (Database for Annotation, Visualization and Integrated Discovery). The gene-gene interaction network was visualised using STRING (Search Tool for the Retrieval of Interacting Genes).

resultsIn CG4 cells treated with 10 ng/ml of EPO and 10 ng/ml of LIF, EPO-induced myelin oligodendrocyte glycoprotein (MOG) expression, measured at day 3 of differentiation, was inhibited ≥4-fold (N = 5, P < 0.001). Inhibition of EPO-induced MOG was also observed with OSM and CNTF. Analysis of the gene expression profile of CG4 differentiating cells treated for 20 h with EPO and LIF revealed LIF inhibition of EPO-induced genes involved in lipid transport and metabolism, previously identified as positive regulators of myelination in this system. In addition, among the genes induced by LIF, and not by differentiation or by EPO, the role of suppressor of cytokine signaling 3 (SOCS3) and toll like receptor 2 (TLR2) as negative regulators of myelination was further explored. LIF-induced SOCS3 was associated with MOG inhibition; Pam3, an agonist of TLR2, inhibited EPO-induced MOG expression, suggesting that TLR2 is functional and its activation decreases myelination.

conclusionsCytokines of the gp130 family may have negative effects on myelination, depending on the cytokine environment.

Indexed as

AnimalsCell LineErythropoietinLeukemia Inhibitory FactorMyelin SheathOligodendrogliaOligonucleotide Array Sequence AnalysisRatsReceptors, ErythropoietinTranscriptomeErythropoietinLeukemia Inhibitory FactorReceptors, ErythropoietinCentral glia-4Multiple sclerosisMyelin oligodendrocyte glycoproteinSOCS3TLR2

Identifiers

PMID30261841
PMCPMC6161334
OpenAlexW2892973298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.